Participated · Equity · Jul 2026

TytoCare develops a clinician-grade handheld remote examination platform paired with FDA-cleared AI-powered software-as-a-medical-device algorithms to enable comprehensive remote physical exams. The company serves health systems, payers, and employer health programs and is positioning its platform for cardiopulmonary screening, oncology supportive care, and chronic disease management including CHF and COPD. TytoCare announced leadership appointments of Adam Pellegrini as CEO and Greg Orr as COO concurrent with its $25M+ growth round led by Insight Partners. The company intends to use the new capital to expand its AI algorithm pipeline, deepen integrations with health systems and payers, and accelerate go-to-market efforts. TytoCare is headquartered in New York and Netanya, Israel, and emphasizes FDA-cleared diagnostic fidelity as a competitive differentiator.

Participated · Series C · Aug 2024

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Led · Equity · Aug 2024

Hexarad offers an end-to-end radiology software suite including a proprietary radiology information system (RIS), the Hexarad Edge integration engine, Hexarad Hub for urgent reporting and Hexarad Portal for auto-allocation. The company also delivers tech-enabled teleradiology services to the NHS and imaging centres across the UK and Ireland and serves customers in Saudi Arabia. Its auto-allocation tool assigns scans 90% more quickly than manual allocation and the platform has attracted over 200 radiologists to date, delivering industry-leading turnaround times and high customer satisfaction. Hexarad’s work has reduced diagnostic waiting times in NHS settings — one deployment saved 14 hours of A&E referral time a night at North West Anglia NHS Foundation. The founding team are NHS consultant radiologists (company founded in 2016) and emphasise clinically led product development. Management and investors plan to scale teleradiology services and expand the company’s software product offerings. Hexarad is an early-stage, high-growth healthcare technology company founded in 2016 by NHS consultant radiologists and led by CEO Dr Farzana Rahman. Its core product, Optirad, is a workflow management software tool that analyses and deploys a radiology department’s workforce to reduce scan reporting delays, with features including rota management, intelligent allocations, business intelligence and supply-and-demand forecasting. Optirad can operate across multiple sites and assign specialist reporting to the most appropriate radiologist. The company plans to use the funds to grow its radiology platform, support more NHS and private healthcare customers, add deeper capability and specialisation to its reporter network, and further improve its core technology. Hexarad positions its technology-driven solutions as addressing key causes of diagnostic delays. Financially, the company has completed a Series A round that now totals £4.5m.

Led · Series B · Sep 2022

Apricity is a virtual fertility clinic launched in the UK in 2018 by CEO Caroline Noublanche and originally incubated by Kamet Ventures. The company combines technology and artificial intelligence with personalised care and medical expertise to improve the fertility experience and maximise chances of conception. It provides access to fertility advisors and a customised treatment journey for patients, all navigated through a mobile app. Apricity assists with every step of the fertility treatment journey and provides continuous, personalised support through its app. The company intends to use funds to accelerate growth in the UK and expand geographically to Spain before the end of the year, followed by Germany and Italy. It also plans to further develop its technology and expand at-home services to include at-home ultrasound scans in select areas. Apricity recently completed a €17m Series B financing. Apricity is a London-based virtual fertility clinic combining medical expertise, human care and new technologies. The company offers bespoke treatment options, nurses available seven days a week, and an app with injection and appointment reminders. It also provides curated videos and articles to help patients. Apricity has launched in the UK and recently acquired Altrui, the UK leader in egg donation services, which brings nearly a decade of experience. The company is led by CEO and co-founder Caroline Noublanche. Financially, Apricity secured €6m in a Series A and has raised €8.8m in total to date.

Led · Series A · Jun 2022

LynxCare provides an AI and Natural Language Processing platform that extracts insights from legacy, siloed hospital data to surface real-world treatment performance and improve patient outcomes. The company notes that an estimated 90% of hospital data remains unused and aims to unlock that information for clinical care and research. Founded in 2015 by Georges De Feu and Dries Hens, LynxCare works with hospitals to operationalize previously inaccessible data. The platform has entered a partnership with PSIH Group, giving 66% of French hospital groups access to its software. The company raised €20 million in a Series A to accelerate the international rollout of its platform and scale adoption. LynxCare is a Leuven-based startup that has developed the LynxCare AI platform to automatically process and display hospital data. The platform analyzes large volumes of unstructured clinical data using tailored, context-specific algorithms the company says deliver higher accuracy and scalable results. Its product is designed to benefit patients, physicians, care staff, and hospital organisations by enabling value-based, results-oriented care. Founded in 2015, LynxCare plans to use the new funding to fuel expansion across Europe and the United States. The company raised €1.8 million in the latest round, following a €1.75 million raise in April, bringing nearly €4 million raised in under a year according to the CEO. Investors and management point to the team’s machine-learning and medical expertise and the company’s commercial traction in clinical data analytics.